SEARCH

SEARCH BY CITATION

References

  • Apondi R, Bunnell R, Awor A et al. (2007) Home-based antiretroviral care is associated with positive social outcomes in a prospective cohort in Uganda. Journal of Acquired Immune Deficiency Syndromes 44, 7176.
  • Auvert B, Taljaard D, Lagarde E et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Medicine 2, e298.
  • Baggaley RF, Garnett GP & Ferguson NM (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Medicine 3, e124.
  • Bailey RC, Moses S, Parker CB et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643656.
  • Bakobaki JM, Lacey CJ, Bukenya M et al. (2005) A randomized controlled safety and acceptability trial of DS gel in sexually active women in Uganda. AIDS 19, 21492156.
  • Bentley ME, Fullem AM, Tolley EE et al. (2004) Acceptability of a Microbicide among women and their partners in a 4-Country phase I trial. American Journal of Public Health 94, 11591164.
  • Buchbinder SP, Mehrotra DV, Duerr A et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 18811893.
  • Castilla J, Del Romero J, Hernando V, Marincovich B, García S & Rodríguez C (2005) Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. Journal of Acquired Immune Deficiency Syndromes 40, 96101.
  • Cates W & Feldblum P (2008) HIV prevention research: the ecstasy and the agony. Lancet 372, 932933.
  • Celum C, Wald A, Hughes J et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371, 21092119.
  • Celum C, Wald A, Lingappa JR et al. (2010) Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. New England Journal of Medicine 362, 427439.
  • Chisembele M, Crook A, Gafos M et al. (2010) PRO2000 Vaginal Gel is Ineffective in Preventing HIV Infection: Results of the MDP301 Phase III Microbicide Trial. CROI Abstract #87LB.
  • DART Trial (2010) Team Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet 375, 123131.
  • Granich RM, Gilks CF, Dye C, De Cock KM & Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373, 4857.
  • Gray RH, Kigozi G, Serwadda D et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657666.
  • Grosskurth H, Mosha F, Todd J et al. (1995) Impact of improved treatment of sexually transmitted diseases on HIV-1 infection in rural Tanzania: randomised controlled trial. Lancet 346, 530536.
  • Guay LA, Musoke P, Fleming T et al. (1999) Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354, 795802.
  • Jaffar S, Amuron B, Foster S et al. (2009) Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet 374, 20802089.
  • Karim SA, Coletti A, Richardson B et al. (2009) Safety and Effectiveness of Vaginal Microbicides BufferGel and 0.5% PRO 2000/5 Gel for the Prevention of HIV Infection in Women: Results of the HPTN 035 Trial. CROI, Abstract #48LB.
  • Klasse PJ, Shattock R & Moore JP (2008) Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annual Review of Medicine 59, 291307.
  • McCormack S, Hayes R, Lacey CJN & Johnson AM (2001) Science, medicine and the future: microbicides in HIV prevention. British Medical Journal 322, 410413.
  • Parkes-Ratanshi R, Kamali A, Wakeham K et al. (2009) Successful Primary Prevention of Cryptococcal Disease Using Fluconazole Prophylaxis in HIV-infected Ugandan Adults.CROI Abstract #32.
  • Pinkerton SD (2008) Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS and Behavior 12, 677684.
  • Ramjee G, Gouws E, Andrews A et al. (2001) The acceptability of a vaginal microbicide among South African men. International Family Planning Perspectives 27, 164170.
  • Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. (2009) Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. New England Journal of Medicine 361, 22092220.
  • Shafer LA, Biraro S, Nakiyingi-Miiro J et al. (2008) HIV prevalence and incidence are no longer falling in southwest Uganda: evidence from a rural population cohort 1989–2005. AIDS 22, 16411649.
  • Shaffer N, Chuachoowong R, Mock PA et al. (1999) Short-course zidovudine for perinatal HIV-1 ransmission in Bangkok, Thailand: a randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 353, 773780.
  • Smith SM (2004) Pre-exposure chemoprophylaxis for HIV: it is time. Retrovirology 1, 16.
  • Smith DK, Grohskopf LA, Black RJ et al. (2005) Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. Morbidity and Mortality Weekly Report 54, 120.
  • Subbarao S, Otten RA, Ramos A et al. (2006) Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. Journal of Infectious Diseases 194, 904911.
  • Tsai CC, Follis KE, Sabo A et al. (1995) Prevention of SIV infection in macaquesby (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270, 11971199.
  • UNAIDS (2009) AIDS Epidemic Update. UNAIDS, Geneva.
  • Vernazza PL, Bruce GL, Dyer J et al. (1997) Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 11, 987993.
  • Wawer JM, Makumbi, F, Kigozi G et al. (2009) Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 374, 229237.
  • Walker LM, Phogat SK, Chan-Hui P et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine. Science 326, 285326.
  • Watson-Jones D, Weiss HA, Rusizoka M et al. (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. New England Journal of Medicine 358, 15601571.
  • WHO/UNAIDS (2005) Update Report. http://www.who.int/3by5 .
  • Wiktor SZ, Ekpini E, Karon JM et al. (1999) Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abdijan, Cote d’Ivoire: a randomised trial. Lancet 353, 781785.
  • Youle M & Wainberg MA (2003) Could chemoprophlaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 17, 937938.
  • Zachariah R, Harries AD, Luo C, Bachman G & Graham SM (2007) Scaling-up co-trimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. The Lancet Infectious Diseases 7, 686693.
  • Zhang H, Dornadula G, Beumont M et al. (1998) Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. New England Journal of Medicine 339, 18031809.